Literature DB >> 12047143

HER2/neu amplification in breast cancer: stratification by tumor type and grade.

Elise R Hoff1, Raymond R Tubbs, Jonathan L Myles, Gary W Procop.   

Abstract

The presence of HER2/neu gene amplification is prognostically and therapeutically significant for patients with breast cancer. We sought to determine whether a relationship exists between HER2/neu gene amplification and the histologic type and grade of tumor. The histologic features and corresponding HER2/neu amplification results of 401 cases of invasive breast carcinoma were reviewed. Lobular carcinomas were less likely than ductal carcinomas to have HER2/neu amplification. Amplification was less frequent in Scarff-Bloom-Richardson grade I ductal carcinomas than in grades 2 and 3. Metastatic carcinomas frequently displayed HER2/neu amplification (6/20 [30%]). Our results support a correlation between HER2/neu amplification and the histologic type and grade of breast cancer. We suggest reexamination of tumors diagnosed as Scarff-Bloom-Richardson grade I invasive ductal carcinomas or lobular carcinomas if the lesion displays HER2/neu amplification to assure the exclusion of a higher grade of lesion or of missed ductal components.

Entities:  

Mesh:

Year:  2002        PMID: 12047143     DOI: 10.1309/4NTU-N6K4-F8JF-EWRX

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  24 in total

1.  Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.

Authors:  Rachel Stevens; Imad Almanaseer; Miguel Gonzalez; Derin Caglar; Ryan A Knudson; Rhett P Ketterling; Daniel S Schrock; Thomas A Seemayer; Julia A Bridge
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 2.  The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Authors:  André Steven; Barbara Seliger
Journal:  Breast Care (Basel)       Date:  2018-02-02       Impact factor: 2.860

3.  Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients.

Authors:  Jing Wei; Bing Han; Xiao-yun Mao; Min-jie Wei; Fan Yao; Feng Jin
Journal:  Tumour Biol       Date:  2011-09-16

4.  Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients).

Authors:  Vahit Özmen
Journal:  J Breast Health       Date:  2014-04-01

5.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

6.  HER2/ERBB2 immunoreactivity in human retinoblastoma.

Authors:  G M Seigel; S Sharma; A S Hackam; Dhaval K Shah
Journal:  Tumour Biol       Date:  2015-11-27

7.  Study of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India.

Authors:  Hardik Dodiya; Amit Patel; Dipal Patel; Ashish Kaushal; D G Vijay
Journal:  Indian J Clin Biochem       Date:  2013-01-03

Review 8.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

9.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

Authors:  Priti Lal; Paulo A Salazar; Marc Ladanyi; Beiyun Chen
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

10.  HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.

Authors:  Katri Köninki; Minna Tanner; Anssi Auvinen; Jorma Isola
Journal:  Breast Cancer Res       Date:  2009-06-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.